全球酒精性肝病的疾病负担及干预策略

摘要/Abstract

摘要： 酒精性肝病(ALD)是全球常见的慢性肝病。由于缺少特异性诊断标志物,早期症状隐匿,就诊率偏低,部分患者确诊时已发展至终末期肝病。持续戒酒是所有针对ALD治疗的基础,但由于存在过度饮酒(AUD),戒酒依从性差,复饮率高,治疗难度大,预后不良。早期发现、早期诊断AUD及ALD并将筛查范围扩展至普通人群是减轻全球ALD疾病负担的关键,需要从国家到地区以及个人等多层面多措施的综合管理。本文在普通人群中扩大了对AUD及ALD筛查与诊断,并为降低ALD疾病负担采取了多种干预措施,为更好管理ALD及AUD提供参考。

关键词: 酒精性肝病, 过度饮酒, 筛查, 疾病负担

张飞宇, 赵金明, 阿迪拉·亚克普, 高沿航. 全球酒精性肝病的疾病负担及干预策略[J]. 肝脏, 2021, 26(11): 1210-1213.

参考文献

[1] Griswold MG, Fullman N, Hawley C, et al. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2018, 392: 1015-1035.
[2] Sepanlou SG, Safiri S, Bisignano C, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol, 2020, 5: 245-266.
[3] Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol, 2020, 5: 167-228.
[4] Serra-Burriel M, Graupera I, Torán P, et al. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol, 2019, 71: 1141-1151.
[5] Colbert S, Thornton L, Richmond R. Smartphone apps for managing alcohol consumption: a literature review. Addict Sci Clin Pract, 2020, 15: 17.
[6] Westwood G, Meredith P, Atkins S, et al. Universal screening for alcohol misuse in acute medical admissions is feasible and identifies patients at high risk of liver disease. J Hepatol, 2017, 67: 559-567.
[7] Victor RG, Lynch K, Li N, et al. A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops. N Engl J Med, 2018, 378: 1291-1301.
[8] Lee BP, Terrault NA. Return to Alcohol Use After Liver Transplant: Patterns and Surveillance. Clin Liver Dis, 2018, 12: 160-164.
[9] Asphaug L, Thiele M, Krag A, et al. Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis. Hepatology, 2020, 71: 2093-2104.
[10] Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut, 2010, 59: 1245-1251.
[11] Thiele M, Madsen BS, Hansen JF, et al. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology, 2018, 154: 1369-1379.
[12] O'Donnell A, Anderson P, Jané-Llopis E, et al. Immediate impact of minimum unit pricing on alcohol purchases in Scotland: controlled interrupted time series analysis for 2015-18. BMJ, 2019, 366:l5274.
[13] Wagenaar AC, Tobler AL, Komro KA. Effects of alcohol tax and price policies on morbidity and mortality: a systematic review. Am J Public Health, 2010, 100: 2270-2278.
[14] Jiang H, Livingston M, Room R, et al. Modelling the effects of alcohol pricing policies on alcohol consumption in subpopulations in Australia. Addiction, 2020, 115: 1038-1049.
[15] Plunk AD, Krauss MJ, Syed-Mohammed H, et al. The Impact of the Minimum Legal Drinking Age on Alcohol-Related Chronic Disease Mortality. Alcohol Clin Exp Res, 2016, 40: 1761-1768.
[16] Kanwal F, Mapaskhi S, Smith D, et al. Implementation of a Population-Based Cirrhosis Identification and Management System. Clin Gastroenterol Hepatol, 2018, 16:1182-1186.e2.
[17] Winder GS, Fernandez AC, Klevering K, et al. Confronting the Crisis of Comorbid Alcohol Use Disorder and Alcohol-Related Liver Disease With a Novel Multidisciplinary Clinic. Psychosomatics, 2020, 61: 238-253.
[18] Williams R, Alexander G, Armstrong I, et al. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet, 2018, 391: 1097-1107.
[19] Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders. Subst Abus, 2016, 37: 20-24.